NGO · France
not in the EU Transparency RegisterThis organization files on consultations without a register number, so its record here is built from its filings alone. Register facts (staff, costs, accreditations) are not available for it.
Counts here are a floor, never a total: they cover the 687 consultation files tracked so far (60,344 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Track FH in PolicySpeak: request access →
Work at FH Europe Foundation/Anhet.f? so we know who speaks for it.
FH Europe Foundation/Anhet.f filed 4 positions between 16 Sept 2025 and 19 May 2026, across 2 of the 687 legislative files tracked here.
Inherited dyslipidemics, in particular family lhypercholesterolaemia (FH) and lipoprotein elevation (a) (Lp (a)), are major but largely invisible threats to cardiovascular health. The moon touches about one in 300 people, the other one in five. These genetic conditions, independent of lifestyle, pose a very high risk of infarction, stroke and premature death.
Filed in French · English published by the European Commission
High lipoprotein(a), [Lp(a)] is one of the strongest inherited and causal risk factors for cardiovascular disease, affecting one in five Europeans. Despite this prevalence, testing rates remain at only 12%. Most citizens are unaware of their elevated risk, leaving prevention opportunities untapped and healthcare systems burdened by avoidable heart attacks, strokes, and aortic valve disease.
Familial hypercholesterolaemia (FH) and elevated lipoprotein(a)[Lp(a)] are the most common, inherited lipid conditions in Europe. They are major drivers of premature heart attacks, strokes and other cardiovascular diseases, yet remain largely invisible to citizens and in public health strategies. Around one in 300 people live with FH and one in five with high Lp(a).
FH Europe Foundation (FHEF) welcomes the European Commissions initiative to develop a Council Recommendation on cardiovascular health checks under the EU Safe Hearts Plan. Cardiovascular diseases remain the leading cause of death and disability in Europe, yet prevention and early detection remain fragmented across Member States.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put FH Europe Foundation/Anhet.f next to another organization. Same files, same register facts, side by side. Compare →
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 72.
Everything on this page comes from FH Europe Foundation/Anhet.f’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.